PET Imaging of the α4β2* Nicotinic Acetylcholine Receptors in Alzheimer’s Disease

No abstract is available for this paper.

• Publication year

  2020

• Venue

  PET and SPECT in Neurology

• Publication date

  2020-10-11

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/978-3-642-54307-4_11
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparison of the novel α4β2 nicotinic acetylcholine receptor PET radioligands (-)-Flubatine and (+)-Flubatine in Healthy Controls

  2019cited by this paper
• Human brain imaging of nicotinic acetylcholine α4β2* receptors using [18F]Nifene: Selectivity, functional activity, toxicity, aging effects, gender effects, and extrathalamic pathways

  2018cited by this paper
• Dual targeting agents for Aβ plaque/P-glycoprotein and Aβ plaque/nicotinic acetylcholine α4β2* receptors—potential approaches to facilitate Aβ plaque removal in Alzheimer’s disease brain

  2018cited by this paper
• Exploring the Metabolism of (+)-[18F]Flubatine In Vitro and In Vivo: LC-MS/MS Aided Identification of Radiometabolites in a Clinical PET Study †

  2018cited by this paper
• 18F-XTRA PET for Enhanced Imaging of the Extrathalamic α4β2 Nicotinic Acetylcholine Receptor

  2018cited by this paper
• Cognitive correlates of α4β2 nicotinic acetylcholine receptors in mild Alzheimer’s dementia

  2018cited by this paper
• Pretangle pathology within cholinergic nucleus basalis neurons coincides with neurotrophic and neurotransmitter receptor gene dysregulation during the progression of Alzheimer's disease.

  2018cited by this paper
• Imaging α4β2 Nicotinic Acetylcholine Receptors (nAChRs) in Baboons with [18F]XTRA, a Radioligand with Improved Specific Binding in Extra-Thalamic Regions

  2017cited by this paper
• Human biodistribution and dosimetry of [18F]nifene, an α4β2* nicotinic acetylcholine receptor PET tracer.

  2017cited by this paper
• [18F]Nifene test–retest reproducibility in first‐in‐human imaging of α4β2* nicotinic acetylcholine receptors

  2017cited by this paper
• Radiation dosimetry of the α4β2 nicotinic receptor ligand (+)-[18F]flubatine, comparing preclinical PET/MRI and PET/CT to first-in-human PET/CT results

  2016cited by this paper
• LC-MS Supported Studies on the in Vitro Metabolism of both Enantiomers of Flubatine and the in Vivo Metabolism of (+)-[18F]Flubatine—A Positron Emission Tomography Radioligand for Imaging α4β2 Nicotinic Acetylcholine Receptors

  2016cited by this paper
• First-in-human PET quantification study of cerebral α4β2* nicotinic acetylcholine receptors using the novel specific radioligand (-)-[18F]Flubatine

  2015cited by this paper
• Role of the nicotinic acetylcholine receptor in Alzheimer's disease pathology and treatment.

  2015cited by this paper
• Comparing α7 nicotinic acetylcholine receptor binding, amyloid‐β deposition, and mitochondria complex‐I function in living brain: A PET study in aged monkeys

  2015cited by this paper
• PET Imaging of High-Affinity α4β2 Nicotinic Acetylcholine Receptors in Humans with 18F-AZAN, a Radioligand with Optimal Brain Kinetics

  2013cited by this paper
• Alterations in α4β2 nicotinic receptors in cognitive decline in Alzheimer's aetiopathology.

  2013cited by this paper
• Differentially decreased α4β2* nicotinic acetylcholine receptor availability (α4β2*-nAChR) in early-onset (EOAD) and late-onset Alzheimer’s disease (LOAD)

  2012cited by this paper
• Effectiveness and Safety of 18F-FDG PET in the Evaluation of Dementia: A Review of the Recent Literature

  2012cited by this paper
• PET Imaging of Nicotinic Acetylcholine Receptors in Baboons with 18F-AZAN, a Radioligand with Improved Brain Kinetics

  2012cited by this paper
• Cerebral alpha4beta2 nicotinic acetylcholine receptors (nAChRs) in early Alzheimer disease (AD) assessed with the new PET tracer (-)-[18F]-norchloro-fluoro-homoepibatidine (NCFHEB)

  2011cited by this paper
• The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

  2011cited by this paper
• Decreased cerebral α4β2* nicotinic acetylcholine receptor availability in patients with mild cognitive impairment and Alzheimer’s disease assessed with positron emission tomography

  2011cited by this paper
• P1‐347: Contrasting default mode abnormalities in Alzheimer's disease revealed by task and passive rest

  2011cited by this paper
• Early-onset versus late-onset Alzheimer's disease: the case of the missing APOE ɛ4 allele.

  2011cited by this paper
• The cholinergic system in aging and neuronal degeneration.

  2011cited by this paper
• Specific α4β2 nicotinic acetylcholine receptor binding of [F‐18]nifene in the rhesus monkey

  2011cited by this paper
• PET/CT in diagnosis of dementia

  2011cited by this paper
• Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade.

  2010cited by this paper
• 5-(123)I-A-85380 binding to the α4β2-nicotinic receptor in mild cognitive impairment.

  2010cited by this paper
• Nicotinic Acetylcholine Receptor Signalling: Roles in Alzheimer's Disease and Amyloid Neuroprotection

  2009cited by this paper
• Reduced alpha4beta2*-nicotinic acetylcholine receptor binding and its relationship to mild cognitive and depressive symptoms in Parkinson disease.

  2009cited by this paper
• 123I-5-IA-85380 SPECT Imaging of Nicotinic Receptors in Alzheimer Disease and Mild Cognitive Impairment

  2009cited by this paper
• In vivo measurement of nicotinic acetylcholine receptors with [18F]norchloro‐fluoro‐homoepibatidine

  2008cited by this paper
• Quantification of nicotinic acetylcholine receptors in the human brain with PET: Bolus plus infusion administration of 2-[18F]F-A85380

  2008cited by this paper
• Relationship between nicotinic receptors and cognitive function in early Alzheimer's disease: a 2-[18F]fluoro-A-85380 PET study.

  2008cited by this paper
• The Black Book of Alzheimer's Disease, Part 1

  2008cited by this paper
• Acetylcholine receptors in dementia and mild cognitive impairment

  2008cited by this paper
• Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands

  2007cited by this paper
• Measurement of the alpha4beta2* nicotinic acetylcholine receptor ligand 2-[(18)F]Fluoro-A-85380 and its metabolites in human blood during PET investigation: a methodological study.

  2007cited by this paper
• Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system.

  2007cited by this paper
• Synthesis procedure for routine production of 2-[18F]fluoro-3-(2(S)-azetidinylmethoxy)pyridine (2-[18F]F-A-85380).

  2007cited by this paper
• A specific amyloid-β protein assembly in the brain impairs memory

  2006cited by this paper
• Cigarette Smoking Saturates Brain α4β2 Nicotinic Acetylcholine Receptors

  2006cited by this paper
• Binding properties of the cerebral α4β2 nicotinic acetylcholine receptor ligand 2-[18F]fluoro-A-85380 to plasma proteins

  2006cited by this paper
• Involvement of the recurrent artery of Heubner with contralateral middle cerebral artery infarction

  2006cited by this paper
• Basal Forebrain Cholinergic Dysfunction in Alzheimer’s Disease – Interrelationship with β-amyloid, Inflammation and Neurotrophin Signaling

  2005cited by this paper
• Quantification of human nicotinic acetylcholine receptors with 123I-5IA SPECT.

  2004cited by this paper
• Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment

  2004cited by this paper
• 6‐[18F]Fluoro‐A‐85380, a new PET tracer for the nicotinic acetylcholine receptor: Studies in the human brain and in vivo demonstration of specific binding in white matter

  2004cited by this paper
• 2 [18F]F‐A85380: PET imaging of brain nicotinic acetylcholine receptors and whole body distribution in humans

  2003cited by this paper
• Alterations in cholinergic and non‐cholinergic neurotransmitter receptor densities in transgenic Tg2576 mouse brain with β‐amyloid plaque pathology

  2003cited by this paper
• Brain acetylcholinesterase activity in mild cognitive impairment and early Alzheimer’s disease

  2003cited by this paper
• Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial.

  2002cited by this paper
• Nicotinic receptor abnormalities of Alzheimer's disease: therapeutic implications.

  2001cited by this paper
• The cholinergic hypothesis of Alzheimer’s disease: a review of progress

  1999cited by this paper
• In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease

  1996cited by this paper
• Alteration in nicotine binding sites in Parkinson's disease, Lewy body dementia and Alzheimer's disease: possible index of early neuropathology.

  1995cited by this paper
• Kinetic Analysis of Regional (S)(-)11C‐Nicotine Binding in Normal and Alzheimer Brains In Vivo Assessment Using Positron Emission Tomography

  1995cited by this paper
• Vascular dementia

  1993cited by this paper
• A postmortem study of brain nicotinic receptors in Parkinson's and Alzheimer's disease.

  1991cited by this paper

• No citing papers are available for this paper.